In June, Morphosys AG acquired Constellation Pharmaceuticals Inc. in a deal worth $1.7 billion in which the German biotech monetizes a royalty from a big-selling antibody, spending the lump sum on research into small-molecule BET inhibitors. It’s a bold move and one that perhaps demonstrates a renewed interest in small-molecule drugs after a period when antibody-based molecules have been the dominant force in the market for branded drugs.
Clive Dix talks Proactive London's Katie Pilbeam about their worldwide licensing deal with international drugs giant Sanofi worth up to €414mln.
The group will receive €7mln upfront, plus €11mln in pre-clinical payments.
The deal is for their oral IL-17A inhibitor programme, currently IL-17 monoclonal antibodies are administered by injection. Having an oral version represents a significant breakthrough.
A new collaboration between Sano Genetics and industry partners aims to accelerate drug and biomarker discovery in ulcerative colitis (UC), a form of Inflammatory Bowel Disease (IBD).
Craig Fox, Chief Scientific Officer, C4X Discovery, added: “Identifying the right drug target for the right patient is a major but challenging goal for drug discovery, particularly for diseases with significant pathophysiological heterogeneity such as ulcerative colitis.
“Our proprietary Taxonomy3 platform will analyse the datasets produced from this research to identify novel drug targets and patient subtypes of UC which may provide a powerful insight into discovering new treatments and enrichment strategies for clinical success.”
Clive Dix talks to Proactive London about taking over as the interim chair of the UK Vaccine Taskforce following the departure of Kate Bingham.
Dix goes on to discuss how this appointment will impact C4X, explaining "if you look at what we've achieved at C4X in the last year, I don't think you'll see a blemish on that productivity".
CEO Clive Dix spoke to Proactive Investors on today’s business update.
Talking about the collaboration with the GEN-COVID Consortium in Italy, Clive said "The disease continues to spread throughout the world and a clear understanding of how it affects people differently remains elusive. We believe that genetics may play a role in explaining the differences in an individual's disease susceptibility, severity and prognosis."
The criticality of venturing into new drugs has been discussed in the earlier segment, and an encouraging step has been taken in this direction. C4X Discovery (C4XD), a leading UK-based drug discovery company which develops new drug combinations for chronic addiction and cancer is credited to create its own VR tool named, 4Sight...
Clive Dix talks Proactive London's Andrew Scott through its interim results to January 2020.
Dix says its NRF-2 activator programme for sickle cell disease and pulmonary arterial hypertension is progressing and it is down to a short-list of three molecules.